

AMENDMENTS TO THE CLAIMS

Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

- 1-25. (Canceled)
26. (Currently amended) A composition comprising a polypeptide comprising at least two antigen binding sites, wherein
said at least two antigen binding sites are located on a single polypeptide chain;
one of said at least two antigen binding sites specifically binds the human CD3 antigen;
the other antigen binding site of said at least two antigen binding sites specifically binds
to the human CD19 antigen;
said polypeptide existing in both monomeric form and multimeric form, said monomeric
form being said single polypeptide chain and said multimeric form comprising at
least two of said single polypeptide chains non-covalently associated with one
another, wherein said multimeric form of said polypeptide constitutes no more
than 3% of the total weight of the combined monomeric and multimeric forms of
said polypeptide; and
said polypeptide has a sequence as depicted in any of SEQ ID NOS: 1-6, and said
composition further comprises a citrate/lysine buffer pH 6.0 - 7.5.
- 27-29. (Canceled)
30. (Withdrawn – Currently amended) A method of producing a composition of claim 26, in
which the amount of the polypeptide in monomeric form has been enriched relative to the
amount of said polypeptide in multimeric form, wherein[[:]]
~~said polypeptide comprises at least two antigen binding sites on a single polypeptide
chain, and one of said at least two antigen binding sites specifically binds the
human CD3 antigen;~~
said polypeptide in monomeric form is said single polypeptide chain; and

~~said polypeptide in multimeric form comprises at least two of said single polypeptide chains non-covalently associated with one another;~~
said method comprising the following steps comprises:

- (a) providing the composition comprising said polypeptide in both multimeric and monomeric forms;
- (b) isolating said polypeptide in both multimeric and monomeric form from said composition, said isolating ~~accomplished by~~ comprising:
 - (i) applying said composition to a first chromatographic material comprising a metal ion;
 - (ii) removing any components of said composition which have not bound to said first chromatographic material by washing said first chromatographic material with a first buffer; and
 - (iii) eluting said polypeptide in both multimeric and monomeric form from said first chromatographic material by applying imidazole to said first chromatographic material in a concentration of at least 60 mM;
 - (iv) collecting a first eluate comprising said polypeptide in multimeric form and said polypeptide in monomeric form;
- (c) performing a separation preparatory step ~~accomplished by~~ comprising:
 - (i) applying said first eluate to a second chromatographic material, which is an ion exchange material;
 - (ii) removing any components of the first eluate which have not bound to said second chromatographic material by washing said second chromatographic material with a second buffer;
 - (iii) eluting said polypeptide in multimeric and monomeric form from said second chromatographic material by applying sodium chloride to said second chromatographic material in a concentration of at least 200 mM;
 - (iv) collecting a second eluate;
- (d) performing a separation of said polypeptide in multimeric form from said polypeptide in monomeric form, said separation comprising ~~accomplished by~~

- (i) applying said second eluate to a third chromatographic material allowing separation on the basis of molecular weight;
 - (ii) translocating components of the applied second eluate along said third chromatographic material by applying a running buffer to said third chromatographic material;
 - (iii) collecting a third eluate in fractions;
- (e) analyzing said fractions of said third eluate individually to obtain a measure of the amount of said polypeptide in monomeric form relative to the amount of polypeptide in multimeric form in each fraction; and
- (f) combining fractions of said third eluate which almost exclusively contain the polypeptide in monomeric form to obtain a composition enriched in the polypeptide in the monomeric form.
31. (Withdrawn) The method of claim 30, wherein steps (b)(ii) and/or (c)(ii) is/are performed by means of chromatography on a column or by means of a batch process, wherein it is preferred that steps (b)(ii) and (c)(ii) are performed on a column.
 32. (Withdrawn) The method of claim 30, wherein said first chromatographic material comprises the Zn^{2+} or the Ni^{2+} ion.
 33. (Withdrawn) The method of claim 30, wherein said second chromatographic material allows separation on the basis of anion exchange.
 34. (Withdrawn) The method of claim 30, wherein said washing of steps (b)(ii) and (c)(ii) are performed using a volume of first and/or second buffer which is 6 to 10 times greater than the volume of the first and/or second chromatographic material, respectively.
 35. (Withdrawn) The method of claim 30, wherein said translocating of step (d)(ii) is accomplished by applying a volume of said running buffer equivalent to 3 to 7 times the volume of the third chromatographic material.
 36. (Withdrawn) The method of claim 30, wherein said first and second buffer are each phosphate buffer pH 8.

37. (Withdrawn – Currently amended) The method of claim 30, wherein said running buffer in step (d)(ii) is ~~selected from phosphate buffer pH 7.0-7.5 and/or~~ citrate/lysine buffer pH 6.0-7.5.
38. (Withdrawn) The method of claim 30, further comprising the step of analyzing the composition enriched in the polypeptide in the monomeric form obtained in step (f) to obtain a measure of the amount of said polypeptide in monomeric form relative to the amount of polypeptide in multimeric form in said composition.
39. (Withdrawn) The method of claim 38, further comprising the step of enriching the content of polypeptide in monomeric form relative to the content of polypeptide in multimeric form by repeating steps (d) through (f) on said composition enriched in the polypeptide in the monomeric form.
40. (Withdrawn) The method of claim 30, wherein said analyzing is performed using a chromatographic method which separates substances on the basis of their molecular weight.
41. (Withdrawn – Currently amended) The method of claim 40, wherein said chromatographic method is size exclusion chromatography, ~~in particular high performance size exclusion chromatography.~~
42. (Withdrawn) The method of claim 30, wherein:

said imidazole is applied either as a concentration gradient or as a single concentration and/or

said sodium chloride is applied either as a concentration gradient or as a single concentration.
43. (Withdrawn – Currently amended) The method of claim 42, wherein:

said imidazole is applied in a single concentration ~~ehosen~~selected from the group consisting of the following concentrations: 70 mM, 80 mM, 90 mM, 100 mM, 110 mM and 120 mM; and

said sodium chloride is applied in a single concentration ~~ehosen~~selected from the group consisting of the following concentrations: 370 mM, 380 mM, 390 mM, 400 mM, 410 mM and 420 mM.

44. (Withdrawn) The method of claim 43, wherein said imidazole is applied in a concentration of 80 mM and/or said sodium chloride is applied in a concentration of 400 mM.
45. (Canceled)
46. (Withdrawn – Currently amended) A method for the prevention, treatment or amelioration of a proliferative disease, a minimal residual cancer, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease, a host-versus-graft disease or a B cell malignancy, the method comprising ~~the~~ step of administering, to a subject in need of such a prevention, treatment or amelioration, a composition of claim 26.
47. (Withdrawn) The method of claim 46, wherein prevention, treatment or amelioration of the disease or disorder occurs in a human.
48. (Withdrawn) The method of claim 46, wherein said tumorous disease is selected from the group consisting of a lymphoma, a B-cell leukemia or a Hodgkin lymphoma.
49. (Withdrawn) The method of claim 46, wherein said B cell malignancy is a non-Hodgkin lymphoma.
50. (Withdrawn) The method of claim 46, wherein said autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, type 1 diabetes mellitus, inflammatory bowel

disease, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.

51. (Canceled)

52. (Currently amended) ~~The composition of claim 26,~~ A composition comprising a polypeptide comprising at least two antigen binding sites, wherein said at least two antigen binding sites are located on a single polypeptide chain; one of said at least two antigen binding sites specifically binds the human CD3 antigen; the other antigen binding site of said at least two antigen binding sites specifically binds to the human CD19 antigen;
said polypeptide existing in both monomeric form and multimeric form, said monomeric form being said single polypeptide chain and said multimeric form comprising at least two of said single polypeptide chains non-covalently associated with one another, wherein said multimeric form of said polypeptide constitutes no more than 2% of the total weight of the combined monomeric and multimeric forms of said polypeptide; and
said polypeptide has a sequence as depicted in any of SEQ ID NOS: 1-6, and said composition further comprises a citrate/lysine buffer pH 6.0 - 7.5.

53. (Currently amended) ~~The composition of claim 26,~~ A composition comprising a polypeptide comprising at least two antigen binding sites, wherein said at least two antigen binding sites are located on a single polypeptide chain; one of said at least two antigen binding sites specifically binds the human CD3 antigen; the other antigen binding site of said at least two antigen binding sites specifically binds to the human CD19 antigen;
said polypeptide existing in both monomeric form and multimeric form, said monomeric form being said single polypeptide chain and said multimeric form comprising at least two of said single polypeptide chains non-covalently associated with one another, wherein said multimeric form of said polypeptide constitutes no more

than 1% of the total weight of the combined monomeric and multimeric forms of said polypeptide; and

said polypeptide has a sequence as depicted in any of SEQ ID NOS: 1-6, and said composition further comprises a citrate/lysine buffer pH 6.0 - 7.5.

54. (Withdrawn – New) The method of claim 41, wherein the size exclusion chromatograph is high performance size exclusion chromatography.